黄芪甲苷Ⅳ调控Nrf2/HO-1/GPX4通路抑制ApoE~(-/-)小鼠铁死亡并改善动脉粥样硬化的机制
[Mechanism of astragaloside Ⅳ modulation of Nrf2/HO-1/GPX4 pathway to inhibit ferroptosis and ameliorate atherosclerosis in ApoE~(-/-) mice].
作者信息
Qin He-Wei, Sun Meng-Yan, Wang Meng-Nan, Liu Dan-Dan, Gao Yang
机构信息
the Second Affiliated Hospital of Henan University of Chinese Medicine Zhengzhou 450002, China.
出版信息
Zhongguo Zhong Yao Za Zhi. 2024 Jul;49(13):3619-3626. doi: 10.19540/j.cnki.cjcmm.20240321.702.
The intervention effect of astragaloside Ⅳ(AS-Ⅳ) on atherosclerosis in apolipoprotein E gene knockout(ApoE)(-/-) mice was observed based on the nuclear factor erythroid-2-related factor 2(Nrf2)/heme oxygenase-1(HO-1)/glutathione peroxidase 4(GPX4) signaling pathway to explore the potential mechanism of AS-Ⅳ in improving ferroptosis in atherosclerotic mice. This study established an atherosclerosis mouse model by feeding them a high-fat diet. After modeling for 8 weeks, ApoE(-/-) mice were randomly divided into the model group, AS-Ⅳ group, AS-Ⅳ+Nrf2 inhibitor(ML385) group, and ferrostatin-1(Fer-1) group. Additionally, a blank control group was also established. Corresponding drugs were administered via intraperitoneal injection, with the control group receiving an equivalent amount of normal saline injection as the model group. After the experiment, serum biochemical levels were measured using an automatic blood lipid analyzer, hematoxylin-eosin(HE) staining was used to observe morphological changes in aortic sinus tissues, colorimetric methods were used to detect levels of ferrous ion(Fe(2+)), malondialdehyde(MDA), glutathione(GSH), and superoxide dismutase(SOD) in mouse serum, immunofluorescence was used to observe the expressions of ferritin heavy chain 1(FTH1) and ferritin light chain(FTL) proteins in the aortic sinus of mice, Western blot was used to detect the protein levels of Nrf2, HO-1, and GPX4 in mouse aortic tissues, and transmission electron microscopy was used to observe ultrastructural changes in aortic tissues. RESULTS:: showed that compared to the control group, the model group of mice had significantly increased calcification and plaque deposition areas in the aortic sinus, increased mitochondrial membrane density, decreased or disappeared mitochondrial cristae, elevated levels of total cholesterol(TC), triglycerides(TG), low-density lipoprotein cholesterol(LDL-C), Fe(2+), and MDA, decreased levels of high-density lipoprotein cholesterol(HDL-C), SOD, and GSH, and significant inhibition of Nrf2, HO-1, GPX4 proteins, as well as iron storage proteins FTH1 and FTL expressions in the aorta. Compared to the model group, AS-Ⅳ treatment resulted in decreased serum TC, TG, LDL-C, Fe(2+), and MDA levels, increased HDL-C, SOD, and GSH levels, increased expressions of Nrf2, HO-1, and GPX4 proteins, and iron storage proteins FTH1 and FTL, and significant improvement in aortic tissue morphology. Compared to the AS-Ⅳ group, the Nrf2 inhibitor ML385 could reverse the therapeutic effect of AS-Ⅳ on atherosclerosis mice. These findings suggest that AS-Ⅳ can inhibit ferroptosis and improve atherosclerosis in ApoE(-/-) mice, and its mechanism of action may be related to the regulation of the Nrf2/HO-1/GPX4 signaling pathway.
基于核因子红细胞2相关因子2(Nrf2)/血红素加氧酶-1(HO-1)/谷胱甘肽过氧化物酶4(GPX4)信号通路,观察黄芪甲苷(AS-Ⅳ)对载脂蛋白E基因敲除(ApoE)-/-小鼠动脉粥样硬化的干预作用,以探讨AS-Ⅳ改善动脉粥样硬化小鼠铁死亡的潜在机制。本研究通过给小鼠喂食高脂饮食建立动脉粥样硬化小鼠模型。建模8周后,将ApoE-/-小鼠随机分为模型组、AS-Ⅳ组、AS-Ⅳ+Nrf2抑制剂(ML385)组和铁死亡抑制剂-1(Fer-1)组。此外,还设立了空白对照组。通过腹腔注射给予相应药物,对照组注射等量生理盐水作为模型组。实验结束后,使用自动血脂分析仪检测血清生化水平,采用苏木精-伊红(HE)染色观察主动脉窦组织的形态变化,采用比色法检测小鼠血清中铁离子(Fe2+)、丙二醛(MDA)、谷胱甘肽(GSH)和超氧化物歧化酶(SOD)水平,采用免疫荧光法观察小鼠主动脉窦中铁蛋白重链1(FTH1)和铁蛋白轻链(FTL)蛋白的表达,采用蛋白质免疫印迹法检测小鼠主动脉组织中Nrf2、HO-1和GPX4的蛋白水平,采用透射电子显微镜观察主动脉组织的超微结构变化。结果显示,与对照组相比,模型组小鼠主动脉窦钙化和斑块沉积面积显著增加,线粒体膜密度增加,线粒体嵴减少或消失,总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、Fe2+和MDA水平升高,高密度脂蛋白胆固醇(HDL-C)、SOD和GSH水平降低,Nrf2、HO-1、GPX4蛋白以及主动脉中铁储存蛋白FTH1和FTL的表达受到显著抑制。与模型组相比,AS-Ⅳ治疗可降低血清TC、TG、LDL-C、Fe2+和MDA水平,升高HDL-C、SOD和GSH水平,增加Nrf2、HO-1和GPX4蛋白以及铁储存蛋白FTH1和FTL的表达,并显著改善主动脉组织形态。与AS-Ⅳ组相比,Nrf2抑制剂ML385可逆转AS-Ⅳ对动脉粥样硬化小鼠的治疗作用。这些结果表明,AS-Ⅳ可抑制ApoE-/-小鼠的铁死亡并改善动脉粥样硬化,其作用机制可能与调节Nrf2/HO-1/GPX4信号通路有关。
相似文献
Chin J Integr Med. 2024-10
Zhongguo Zhong Yao Za Zhi. 2024-8
Nan Fang Yi Ke Da Xue Xue Bao. 2024-6-20
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024-5
引用本文的文献
Pharmaceuticals (Basel). 2025-3-14